Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 2/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15210602 | 1.00 | CNR1 (0.39) | CNR1ERN1PDE4CJAK2JAK1 | |
| SCHEMBL15220278 | 1.00 | CNR1 (0.39) | CNR1ERN1PDE4CJAK2JAK1 | |
| SCHEMBL15220282 | 0.98 | CNR1 (0.41) | CNR1ERN1PDE4CJAK2JAK1 | |
| SCHEMBL15210502 | 0.98 | CNR1 (0.41) | CNR1ERN1PDE4CJAK2JAK1 | |
| SCHEMBL15210408 | 0.98 | CNR1 (0.41) | CNR1ERN1PDE4CJAK2JAK1 | |
| SCHEMBL15210583 | 0.91 | ERN1 (0.38) | ERN1PDE4CJAK2JAK1TYK2 | |
| SCHEMBL10267295 | 0.90 | SYK (0.42) | ERN1PDE4CJAK2JAK1TYK2 | |
| SCHEMBL10269029 | 0.90 | SYK (0.42) | ERN1PDE4CJAK2JAK1TYK2 | |
| SCHEMBL18081481 | 0.88 | ERN1 (0.37) | ERN1PDE4CJAK2JAK1TYK2 | |
| SCHEMBL15210490 | 0.88 | FYN (0.40) | PDE4CJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817313-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-07 | — | — | EP | claimed |
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | US | claimed |
| EP-2817313-A1 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | claimed |
| WO-2013124025-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | claimed |
| EP-2817313-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | US | disclosed |
| EP-2817313-A1 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013124025-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | SYK, LYN, BTK | CNR1 2658/4885ERN1 1014/4885PDE4C 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.